A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) (NCT06411249)
A Phase 4, Multicenter, Prospective, Open-Label Study Describing the Efficacy and Safety of Belimumab Administered Subcutaneously in Adult Participants With Early Systemic Lupus Erythematosus
🩺 Plain-English Summary (8th-Grade Level)
This is a prospective, open-label, single arm 3-year clinical study to describe the short-term and long-term efficacy and safety of belimumab in participants with autoantibody positive early SLE with ongoing disease activity despite stable first-line SLE therapy.
Who can join: Review the eligibility criteria below.
Location: GSK Investigational Site — Anniston, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (114 Sites)
Showing the first 25 of 114 sites.
- GSK Investigational Site — Anniston, Alabama
- GSK Investigational Site — Flagstaff, Arizona
- GSK Investigational Site — Mesa, Arizona
- GSK Investigational Site — Tucson, Arizona
- GSK Investigational Site — Covina, California
- GSK Investigational Site — Fontana, California
- GSK Investigational Site — Fullerton, California
- GSK Investigational Site — Long Beach, California
- GSK Investigational Site — Los Angeles, California
- GSK Investigational Site — Mission Hills, California
- GSK Investigational Site — San Diego, California
- GSK Investigational Site — Temecula, California
- GSK Investigational Site — Tujunga, California
- GSK Investigational Site — Van Nuys, California
- GSK Investigational Site — Van Nuys, California
- GSK Investigational Site — Whittier, California
- GSK Investigational Site — Aventura, Florida
- GSK Investigational Site — Clearwater, Florida
- GSK Investigational Site — Miami, Florida
- GSK Investigational Site — Tamarac, Florida
- GSK Investigational Site — Tampa, Florida
- GSK Investigational Site — Atlanta, Georgia
- GSK Investigational Site — Sugar Hill, Georgia
- GSK Investigational Site — Morton Grove, Illinois
- GSK Investigational Site — Rockford, Illinois
📞 Contact the Study Coordinator
Phone: (877) 379-3718
Email: GSKClinicalSupportHD@gsk.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Systemic Lupus Erythematosus
- A Study of Obexelimab in Patients With Systemic Lupus Erythematosus — Peoria, Arizona
- A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus — Anniston, Alabama
- REACH (Restore Energy, Activity Can Help) Lupus Study — Boston, Massachusetts
- Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus — Birmingham, Alabama
- A Treatment Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice — Innsbruck, Tyrol
- A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) — Birmingham, Alabama
Explore by condition: All Systemic Lupus Erythematosus clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.